Peripheral Polyfunctional PD1+ CD8+ T cells demonstrated strong immune protection in non-small cell lung cancer

Yanyan Liu; Ping Lu; Yifei Ma; Zhucheng Yin; Hongli Xu; Lanxin Xiang; Wangli Zhang; Siwei Li; Xinjun Liang

doi:10.1002/eji.202149570

Peripheral Polyfunctional PD1⁺ CD8⁺ T cells demonstrated strong immune protection in non-small cell lung cancer

Eur J Immunol. 2022 Aug;52(8):1369-1371. doi: 10.1002/eji.202149570. Epub 2022 Jun 22.

Authors

Yanyan Liu¹, Ping Lu², Yifei Ma², Zhucheng Yin², Hongli Xu², Lanxin Xiang³, Wangli Zhang³, Siwei Li^{4

5}, Xinjun Liang²

Affiliations

¹ Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.
² Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.
³ College of Life Science and Technology, Huazhong Agricultural University, Wuhan, P. R. China.
⁴ Department of Oncology, Huangzhou District Renmin Hospital, Wuhan, P. R. China.
⁵ Department of Radiation Oncology, The Affiliated Hospital of Guilin Medical University, Guilin, P. R. China.

Abstract

Higher frequencies of polyfunctional PD1⁺ CD8⁺ T cells exhibited a stronger capacity to kill tumor cells in vitro and in vivo experiments. These results suggested that peripheral polyfunctional PD1⁺ CD8⁺ T cells demonstrated strong immune protection. This study also provided a potential combined treatment strategy with anti-PD1 and CAR-T therapy.

Keywords: NSCLC; PD1+CD8+ T cell; polyfunctional.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

CD8-Positive T-Lymphocytes
Carcinoma, Non-Small-Cell Lung* / therapy
Humans
Lung Neoplasms*
Programmed Cell Death 1 Receptor

Substances

Programmed Cell Death 1 Receptor